Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.160
-0.160 (-12.12%)
At close: Sep 21, 2026, 4:00 PM EDT
1.160
0.00 (0.00%)
After-hours: Sep 21, 2026, 4:10 PM EDT
Biofrontera Employees
As of December 31, 2025, Biofrontera had 94 total employees, including 84 full-time and 10 part-time employees. The number of employees increased by 1 or 1.08% compared to the previous year.
Employees
94
Change (1Y)
1
Growth (1Y)
1.08%
Revenue / Employee
$491,223
Profits / Employee
-$67,713
Market Cap
17.23M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 94 | 1 | 1.08% | 84 | 10 |
| Dec 31, 2024 | 93 | 8 | 9.41% | 92 | 1 |
| Dec 31, 2023 | 85 | 4 | 4.94% | 83 | 2 |
| Dec 31, 2022 | 81 | 12 | 17.39% | 81 | 0 |
| Dec 31, 2021 | 69 | 13 | 23.21% | 69 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Universe Pharmaceuticals INC | 216 |
| China Pharma Holdings | 215 |
| Rockwell Medical | 157 |
| Aytu BioPharma | 83 |
| SCYNEXIS | 18 |
| Incannex Healthcare | 12 |
| Talphera | 12 |
| InMed Pharmaceuticals | 6 |
BFRI News
- 7 days ago - Biofrontera announces FDA approval of Ameluz supplemental new drug application - TheFly
- 7 days ago - Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma - GlobeNewsWire
- 11 days ago - FDA approves label update for Biofrontera’s Ameluz Gel - TheFly
- 5 weeks ago - Biofrontera Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Biofrontera Earnings release: Q2 2026 - Filings
- 5 weeks ago - Biofrontera Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth - GlobeNewsWire
- 6 weeks ago - Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026 - GlobeNewsWire